Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) [Phase 3]
Phase 3 trial update for Zevalin after R-CVP in previously untreated follicular lymphoma; study status terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial investigates a genetically engineered lymphocyte therapy given after peripheral blood stem cell transplant in pat…
-
FDA approval · 2021-12-17FDA Approved: COPIKTRA — Supplemental Application (Secura Bio, Inc)
The FDA has approved a supplemental application for COPIKTRA (duvelisib) by Secura Bio, Inc.
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy [Phase 3]
Phase 3 trial evaluating Zevalin vs observation in older patients with newly diagnosed DLBCL achieving PET-negative complete remission after…
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant [Phase 3]
Phase 3 trial comparing pixantrone + rituximab versus gemcitabine + rituximab in aggressive B-cell non-Hodgkin lymphoma and follicular grade…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma [Phase 2]
Phase II trial evaluating weekly bortezomib with Tositumomab and I-131 in relapsed or refractory follicular non-Hodgkin's lymphoma has termi…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) [Phase 2]
Phase 2 study of zanubrutinib (BGB-3111) in Chinese participants with Diffuse Large B-Cell Lymphoma (non-GCB) and indolent lymphomas (Follic…
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.
-
FDA approval · 2021-10-14FDA Approved: LENALIDOMIDE — Original Application (Dr. Reddy's Laboratories Inc.)
The FDA approved Dr. Reddy's Laboratories' original application for lenalidomide (generic), authorizing a generic version of the cancer drug…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide in combination with rituximab for various stage III/IV indolent non-Hodgkin lymphoma subtypes; study c…
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 trial of TAK-659 as a single agent in adult East Asian participants with various non-Hodgkin lymphoma subtypes was terminated.
-
FDA approval · 2021-08-31FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation. The action expands or updates the …
-
CLINICAL_TRIALS trial_result · 2021-08-24Clinical Trial Update: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma [Phase 4]
An open-label, single-arm Phase 4 trial evaluating a short-duration infusion of obinutuzumab in patients with previously untreated advanced …
-
FDA approval · 2021-08-05FDA Approved: LENALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for lenalidomide by Teva Pharmaceuticals, approving changes related to the drug's use.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial of ABT-263 in relapsed or refractory lymphoid malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A phase 1/2 trial investigating obinutuzumab with idasanutlin and venetoclax in relapsed/refractory follicular lymphoma and rituximab with i…
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: TGR1202 in Relapsed and Refractory Follicular Lymphoma [Phase 2]
Phase 2 trial update for TGR1202 in relapsed/refractory follicular lymphoma; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]
Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-22Clinical Trial Update: Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status [Phase 2]
Phase 2 trial exploring adjustment of chemotherapy duration in follicular lymphoma based on minimal residual disease status.
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) [Phase 3]
Phase 3 trial updates for GP2013 in previously untreated, advanced follicular lymphoma have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 trial evaluating lenalidomide with low-dose dexamethasone and rituximab in rituximab-resistant, non-aggressive B-cell lymphomas; com…
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: FCM Versus R-FCM Followed by R-Maintenance or Observation Only [Phase 3]
Phase 3 trial comparing FCM vs R-FCM followed by R-maintenance or observation in follicular and low-grade lymphomas; current status is unkno…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bortezomib, rituximab, dexamethasone with or without temsirolimus in untreated or relapsed Waldenström macroglobu…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study [Phase 4]
A multicenter Phase 4 trial evaluating rituximab maintenance after BR or RCHOP or R2 in newly diagnosed follicular lymphoma.